Another phase I/II trial of a combination regimen (i.e., tazemetostat, the anti-PD-1 nivolumab, and the anti-CTLA-4 ipilimumab) in SMARCB1 or SMARCA4-deficient neoplasms has just been designed (NCT05407441) (Table 3). This evidence concerns the gene SMARCB1 and neoplasm.